Navigation Links
2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Date:9/10/2007

ROCHESTER, Minn. -- In lifesaving procedures to open blocked heart arteries a key question has persisted for years: Is use of the more expensive drug, abciximab, justified over use of the less-expensive eptifibatide"

A new Mayo Clinic study to be published in the current edition of Value in Health, Volume 11, Issue 4 and now available as an e-publication, offers clinicians the first large-scale contemporary study to help answer the question. The study found no significant difference between the drugs in the length of hospital stay or in the rate of cardiovascular event rates.

Our results provide data to show using the lower cost drug does not jeopardize patient health in contemporary percutaneous coronary intervention practice, explains the studys lead author, Kirsten Hall Long, Ph.D. Percutaneous coronary intervention (PCI), also known as angioplasty, is a procedure in which a balloon-tipped catheter is inserted into the narrowed vessel. The balloon is inflated and improves blood flow.

Researchers reviewed records of all Mayo Clinic patients who underwent PCI from November 2000 to August 2004. Of these, 2,123 patients received eptifibatide, and 951 received abciximab.

It is not likely that there will ever be a randomized clinical trial comparing the two drugs, as it would require over 30,000 patients, says Henry Ting, M.D., Mayo Clinic cardiologist and co-author. Our study fills an evidence gap by providing data to help guide treatment decisions.

Value in Health is a multidisciplinary peer-reviewed journal reporting on evaluations of medical technologies including pharmaceuticals, biologics, devices, procedures and other health care interventions. It provides a scientific forum for communicating health economics and outcomes research methods and findings. The journal is a publication of the International Society for Pharmacoeconomics and Outcomes Research.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Cancer drugs in development nearly doubled since 1995
5. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
6. African HIV strains more resistant to anti HIV drugs
7. Emphasis to ban Drugs ads by Doctors
8. Right drugs drastically cut stroke risk
9. Osteoporosis Drugs: right time to take-off
10. Drugs disrupt formation of blood vessels
11. Relating heart protection and antihypertensive drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, ... announced today that a new solution for Emergency Departments (ED) has been added ... space in Emergency Department examination rooms, and with a simplified pallet of information ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... Plainsboro, NJ (PRWEB) , ... December 08, 2016 , ... ... patients, cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts ... In making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching of ... Unified Instance Manager architecture, meeting the needs of multichannel growth and doubling ... unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The report forecasts the global optical transceiver ... 2016-2020. The report covers the present scenario and ... To calculate the market size, the report considers the revenue generated ...
(Date:12/9/2016)... Dec. 9, 2016  Harmar Mobility, LLC announced today that Steven ... of the Board of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... ... Mr. Dawson,s executive career includes ... across a variety of industries. He brings to the company deep ...
(Date:12/9/2016)... Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... of Physiocrine-based therapeutics to address severe, rare diseases, today announced that ... BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel ... 14, 2016, at 4:20 p.m. ET. About aTyr ... aTyr ...
Breaking Medicine Technology: